William Blair analyst Andy Hsieh has reiterated their neutral stance on LNTH stock, giving a Hold rating on November 1.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andy Hsieh has given his Hold rating due to a combination of factors surrounding Lantheus’s current market position and future prospects. The company reported slightly better-than-expected revenues for Pylarify in the third quarter, indicating some stabilization in pricing after recent renegotiations and market share reductions. However, the anticipated volume growth is expected to be offset by ongoing 340B pricing renegotiations, which could lead to further price compression.
Additionally, while there are promising developments such as the FDA’s acceptance of the NDA for MK-6240, a tau PET imaging agent for Alzheimer’s disease, and the upcoming PDUFA date for LNTH-2501, these factors are balanced by the near-term uncertainties. The leadership transition, with the retirement of CEO Brian Markison and the departure of President Paul Blanchfield, adds another layer of uncertainty. Given these mixed signals, Andy Hsieh maintains a Hold rating, reflecting a cautious outlook on Lantheus’s stock performance in the near term.
Hsieh covers the Healthcare sector, focusing on stocks such as Exelixis, Skye Bioscience, and Viking Therapeutics. According to TipRanks, Hsieh has an average return of 8.2% and a 45.81% success rate on recommended stocks.
In another report released on November 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $63.00 price target.